[Systemic treatment for hepatocellular carcinoma].
Hepatocellular carcinoma (HCC) is one of the most frequent malignancies worldwide. A variety of pharmacological strategies has been evaluated in the treatment of HCC: classical chemotherapy, tamoxifen, octreotide, thymostimulin, pravastatin, (131)I-lipiodol as well as transarterial chemoperfusion (TAC) and chemoembolisation (TACE). TACE monotherapy or TACE combined with pravastatin resulted in a survival benefit of selected HCC patients. New strategies such as immunotherapy, antiangiogenic agents or cyclooxygenase inhibitors are under clinical investigation and might play a role in future therapies for HCC. Efficient strategies for the primary prevention of HCC are available and promising concepts in the secondary prevention have been reported.
Spangenberg
H C
HC
Abteilung Innere Medizin II, Medizinische Universitätsklinik Albert-Ludwigs-Universität Freiburg, Germany.
Zuber-Jerger
I
I
Thimme
R
R
Blum
H E
HE
Von Weizsäcker
F
F
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000517:prevention & control; D016461:Chemoembolization, Therapeutic; D003510:Cyclohexanes; D004195:Disease Models, Animal; D015316:Genetic Therapy; D006801:Humans; D007167:Immunotherapy; D008113:Liver Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000517:prevention & control; D015201:Meta-Analysis as Topic; D051379:Mice; D015337:Multicenter Studies as Topic; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D015282:Octreotide / Q000627:therapeutic use; D010865:Pilot Projects; D017035:Pravastatin / Q000627:therapeutic use; D011322:Primary Prevention; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D012717:Sesquiterpenes / Q000627:therapeutic use; D013629:Tamoxifen / Q000008:administration & dosage / Q000627:therapeutic use; D013949:Thymus Extracts / Q000627:therapeutic use; D013997:Time Factors
D000276:Adjuvants, Immunologic; D020533:Angiogenesis Inhibitors; D000903:Antibiotics, Antineoplastic; D000924:Anticholesteremic Agents; D018931:Antineoplastic Agents, Hormonal; D003510:Cyclohexanes; D012717:Sesquiterpenes; D013949:Thymus Extracts; C031407:thymostimulin; D013629:Tamoxifen; D017035:Pravastatin; D015282:Octreotide; D000077609:O-(Chloroacetylcarbamoyl)fumagillol